Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal fentanyl dose-titration and placebo-controlled crossover trial for breakthrough cancer pain
2010-021096-85Phase 3Completed
- Sponsor
- Nycomed
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fentanyl in breakthrough pain and cancer (2 arms), sponsored by Nycomed. Primary endpoint: Pain intensity difference at 10 minutes. Started Feb 2011; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough paincancer
Beyond the preview
Go deeper on 2010-021096-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021096-85.